Delisting riskPopularity #5,242
Retractable Technologies (RVP)
Makes retractable syringes, safety needles, and blood-collection devices.
$0.6950
After hours+0.01 (+1.76%)
At close$0.6830(−3.79%)
In millions of USD, except per-share figures
| In millions | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 14 | 8 | 6 | 10 | 9 | 8 | 10 | 10 | 9 | 7 | 7 |
| Cost of revenue | 13 | 6 | 6 | 10 | 12 | 8 | 11 | 8 | 11 | 7 | 7 |
| Gross profit | 2 | 2 | 0 | 0 | −2 | 0 | 0 | 2 | −2 | 0 | 0 |
| 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 6 | 6 | 5 | |
| Research & development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 4 | 5 | 5 | 5 | 5 | 4 | 5 | 5 | 5 | 5 | 5 | |
| Selling & marketing | 1 | 1 | 1 | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 2 |
| General & administrative | 3 | 3 | 4 | 3 | 3 | 3 | 3 | 4 | 3 | 3 | 4 |
| Other expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| Operating income | −3 | −3 | −6 | −5 | −7 | −5 | −5 | −4 | −8 | −6 | −5 |
| 3 | 4 | 0 | 3 | 11 | −6 | 5 | 4 | 5 | 2 | 8 | |
| Interest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | −3 | −4 | 0 | −3 | −11 | 6 | −5 | −4 | −5 | −2 | −8 |
| Income before tax | 0 | 1 | −6 | −2 | 4 | −10 | 0 | 0 | −2 | −4 | 3 |
| Income tax expense | 0 | 0 | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | 0 | 0 | −14 | −2 | 4 | −11 | 0 | 0 | −2 | −4 | 3 |
| Net income | 0 | 0 | −14 | −2 | 4 | −11 | 0 | 0 | −2 | −4 | 3 |
| EPS, basic | −$0.00 | $0.01 | −$0.48 | −$0.07 | $0.12 | −$0.35 | −$0.00 | $0.01 | −$0.08 | −$0.14 | $0.09 |
| EPS, diluted | −$0.00 | $0.01 | −$0.48 | −$0.07 | $0.12 | −$0.35 | −$0.00 | $0.01 | −$0.08 | −$0.14 | $0.09 |
| Weighted average shares, basic | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 |
| Weighted average shares, diluted | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 |
| EBITDA | 2 | 2 | −4 | 0 | 6 | −8 | 2 | 2 | 0 | −2 | 5 |
| Depreciation & amortization | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| EBIT | 0 | 1 | −6 | −2 | 4 | −10 | 0 | 0 | −2 | −4 | 3 |